Renal protective effect of sirtuin 1.
Silent information regulator 2 (Sir2) is a nicotinamide adenine dinucleotide- (NAD(+)-) dependent deacetylase. The homology of SIRT1 and Sir2 has been extensively studied. SIRT1 deacetylates target proteins using the coenzyme NAD(+) and is therefore linked to cellular energy metabolism and the redox state through multiple signalling and survival pathways. During the past decade, investigators have reported that SIRT1 activity is essential in cancer, neurodegenerative diseases, diabetes, cardiovascular disease, and other age-related diseases. In the kidneys, SIRT1 may inhibit renal cell apoptosis, inflammation, and fibrosis. Therefore its activation may also become a new therapeutic target in the patients with chronic kidney disease including diabetic nephropathy. In this paper, we would like to review the protective functions of sirtuins and the role of SIRT1 in the onset of kidney disease based on previous studies, including diabetic nephropathy, acute renal injury, chronic kidney disease as well as lupus nephritis.
Department of Nephrology, First Hospital of Jilin University, Changchun 130021, China.
Yi-jun
YJ
Dong
Department of Urology, First Hospital of Jilin University, Changchun 130021, China.
Nian
N
Liu
Department of Nephrology, Second Hospital of Jilin University, Changchun 130021, China.
Zhi
Z
Xiao
Department of Nephrology, First Hospital of Jilin University, Changchun 130021, China.
Tao
T
Sun
Department of the Integrated Traditional Chinese and Western Medicine, Second Hospital of Jilin University, Changchun 130021, China.
Shu-hui
SH
Wu
Department of Nephrology, First Hospital of Jilin University, Changchun 130021, China.
Wei-xia
WX
Sun
Department of Nephrology, First Hospital of Jilin University, Changchun 130021, China.
Zhong-gao
ZG
Xu
Department of Nephrology, First Hospital of Jilin University, Changchun 130021, China.
Hang
H
Yuan
D000818:Animals; D004789:Enzyme Activation; D020536:Enzyme Activators / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology; D007674:Kidney Diseases / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology; D015398:Signal Transduction; D056564:Sirtuin 1 / Q000378:metabolism*; D064804:Urological Agents / Q000627:therapeutic use
D020536:Enzyme Activators; D064804:Urological Agents; D056564:Sirtuin 1